ATE553205T1 - Verwendung von dns-sequenzen mit triplex-structur zum transfer von nukleotidsequenzen - Google Patents

Verwendung von dns-sequenzen mit triplex-structur zum transfer von nukleotidsequenzen

Info

Publication number
ATE553205T1
ATE553205T1 AT99915829T AT99915829T ATE553205T1 AT E553205 T1 ATE553205 T1 AT E553205T1 AT 99915829 T AT99915829 T AT 99915829T AT 99915829 T AT99915829 T AT 99915829T AT E553205 T1 ATE553205 T1 AT E553205T1
Authority
AT
Austria
Prior art keywords
retroviral
recombinant
regulators
particles
sequence
Prior art date
Application number
AT99915829T
Other languages
English (en)
Inventor
Pierre Charneau
Veronique Zennou
Hueseyin Firat
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE553205T1 publication Critical patent/ATE553205T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99915829T 1998-04-24 1999-04-23 Verwendung von dns-sequenzen mit triplex-structur zum transfer von nukleotidsequenzen ATE553205T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9805197A FR2777909B1 (fr) 1998-04-24 1998-04-24 Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
PCT/FR1999/000974 WO1999055892A1 (fr) 1998-04-24 1999-04-23 Utilisation de sequences d'adn de structure triplex pour le transfert de sequences nucleotidiques

Publications (1)

Publication Number Publication Date
ATE553205T1 true ATE553205T1 (de) 2012-04-15

Family

ID=9525665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99915829T ATE553205T1 (de) 1998-04-24 1999-04-23 Verwendung von dns-sequenzen mit triplex-structur zum transfer von nukleotidsequenzen

Country Status (12)

Country Link
US (6) US6682907B1 (de)
EP (2) EP2292778B1 (de)
JP (1) JP4571306B2 (de)
AT (1) ATE553205T1 (de)
AU (1) AU3427299A (de)
CA (1) CA2326719C (de)
CY (1) CY1112985T1 (de)
DK (1) DK1071804T3 (de)
ES (2) ES2607484T3 (de)
FR (1) FR2777909B1 (de)
PT (1) PT1071804E (de)
WO (1) WO1999055892A1 (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
EP2169073B1 (de) * 1999-10-11 2013-11-13 Institut Pasteur Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
WO2001027304A2 (en) 1999-10-12 2001-04-19 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US7419829B2 (en) * 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2003012054A2 (en) * 2001-08-02 2003-02-13 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
CA2462628C (en) 2001-10-02 2019-08-20 Institut Clayton De La Recherche Restricted expression lentiviral vectors
US20030194392A1 (en) * 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
WO2004036188A2 (en) * 2002-10-18 2004-04-29 Cylene Pharmaceuticals, Inc. Processes for identifying quadruplex-targeted antiviral molecules
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
EP1748067A1 (de) 2005-07-29 2007-01-31 Institut Pasteur Polynukleotide, die für MHC Klasse I-beschränkte Epitope der hTERT, Analoge und Polyepitope kodieren
EP3293266B1 (de) 2007-05-04 2025-12-24 University Health Network Il-12-immuntherapie gegen krebs
JP2011517409A (ja) * 2008-03-28 2011-06-09 バイレクシス コーポレイション レンチウイルスベースの免疫原性ベクター
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
EP2385107B1 (de) 2010-05-03 2016-08-24 Institut Pasteur Auf Lentivirusvektor basierende immunologische Verbindungen gegen Malaria
EP2666477A1 (de) 2012-05-23 2013-11-27 Theravectys Lentivirale Vektoren mit einem MHC-Klasse-I-Promotor
EP2643343A1 (de) 2010-11-26 2013-10-02 Institut Pasteur Identifizierung eines menschlichen gyrovirus und anwendungen
CN105821078A (zh) 2010-12-09 2016-08-03 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法
AU2012267512B2 (en) 2011-06-10 2014-11-20 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
JP6066356B2 (ja) 2011-09-23 2017-01-25 ブルーバード バイオ， インコーポレイテッド 改善された遺伝子治療方法
EP3269802B1 (de) 2011-09-30 2019-10-23 Bluebird Bio, Inc. Verbindungen zur verbesserten viralen transduktion
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
EP2788477A2 (de) 2011-12-07 2014-10-15 Institut Pasteur Identifizierung des porcinen parecho-like virus und anwendungen
JP6215223B2 (ja) 2011-12-09 2017-10-18 アンスティテュ・パストゥール マルチプレックス免疫スクリーニングアッセイ
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
US20150182617A1 (en) 2012-07-25 2015-07-02 Theravectys Glycoproteins for pseudotyping lentivectors
AU2013352156B2 (en) 2012-11-27 2018-12-06 Children's Medical Center Corporation Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
CA2907397C (en) 2013-03-15 2022-11-22 Anthrogenesis Corporation Modified t lymphocytes
EP2878667A1 (de) 2013-11-29 2015-06-03 Institut Pasteur TAL-Effektormittel zur partiellen oder vollständigen Deletion von DNA-Tandem-Repeats
EP3738597A1 (de) 2014-04-25 2020-11-18 Bluebird Bio, Inc. Verbesserte verfahren zur herstellung adoptiver zelltherapien
IL296691B2 (en) 2014-04-25 2023-11-01 2Seventy Bio Inc MND promoter chimeric antigen receptors
ES2744186T3 (es) 2014-04-25 2020-02-24 Childrens Medical Center Composiciones y métodos para tratar las hemoglobinopatías
CN106793780B (zh) 2014-06-06 2020-05-26 蓝鸟生物公司 改善的t细胞组合物
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EP3031923A1 (de) 2014-12-11 2016-06-15 Institut Pasteur Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis
EP3971210A1 (de) 2014-12-12 2022-03-23 2seventy bio, Inc. Zusammensetzung zur verwendung bei der behandlung von mit b-zellen verbundenen störungen bei einem subjekt, das dessen bedarf, umfasstend eine effektorzelle, die bcma-chimärische antigenrezeptoren umfasst
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
WO2016128549A1 (en) 2015-02-13 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
ES2835861T5 (en) 2015-05-08 2025-02-18 Childrens Medical Ct Corp Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
ES2911015T3 (es) 2015-08-31 2022-05-17 Helixmith Co Ltd Receptores quiméricos de antígeno anti-sialil Tn
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
WO2017134265A1 (en) 2016-02-05 2017-08-10 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
RU2021103425A (ru) 2016-02-12 2021-02-25 Блубёрд Био, Инк. Композиции, повышающие число копий вектора (чкв), и способы их применения
EP3413896B1 (de) 2016-02-12 2021-03-17 Bluebird Bio, Inc. Vcn-förderer-zusammensetzungen und verfahren zur verwendung davon
EP3211003A1 (de) 2016-02-24 2017-08-30 Institut Pasteur T-zell-rezeptoren aus dem hiv-spezifischen repertoire, mittel zu deren herstellung und therapeutische verwendung davon
EP3443001B1 (de) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. Regulierte bioschaltkreissysteme
WO2017180993A1 (en) 2016-04-14 2017-10-19 Bluebird Bio, Inc. Salvage chimeric antigen receptor systems
MX2018013352A (es) 2016-05-03 2019-08-01 Univ Wayne State Metodo para mejorar suministro de genes mediado por virus en el ojo usando inhibidores de proteosoma.
WO2018035141A1 (en) 2016-08-16 2018-02-22 Bluebird Bio, Inc. Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
CA3034782A1 (en) 2016-08-23 2018-03-01 Bluebird Bio, Inc. Tim3 homing endonuclease variants, compositions, and methods of use
BR112019004629A2 (pt) 2016-09-08 2019-10-01 Bluebird Bio, Inc. variantes de endonuclease de homing pd-1, composições e métodos de uso
MA46543A (fr) 2016-10-17 2019-08-21 Bluebird Bio Inc Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
KR20240005168A (ko) 2016-11-04 2024-01-11 2세븐티 바이오, 인코포레이티드 항-bcma car t 세포 조성물
DK3541833T5 (da) 2016-11-17 2024-09-02 2Seventy Bio Inc TGFß signalkonverter
EP3357506A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Mehrere malaria-prä-erythrozyten-antigene und deren verwendung bei der auslösung einer schützenden immunantwort in einem wirt
EP3357504A1 (de) 2017-02-02 2018-08-08 Institut Pasteur Funktionelles screening von antigenen polypeptiden verwendung zur identifizierung von antigenen zur anregung einer schützenden immunantwort und zur auswahl von antigenen mit optimaler schutzwirkung
US10675328B2 (en) 2017-02-14 2020-06-09 Children's Hospital Medical Center Compositions and methods for treatment of Gcase related disease states
AU2018221730B2 (en) 2017-02-15 2024-06-20 Novo Nordisk A/S Donor repair templates multiplex genome editing
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
EP3630962A4 (de) 2017-05-25 2021-01-20 Bluebird Bio, Inc. Cblb-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung
WO2019070974A1 (en) 2017-10-04 2019-04-11 Bluebird Bio, Inc. PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
US12522811B2 (en) 2018-05-01 2026-01-13 The Children's Medical Center Corporation Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9
WO2019213013A1 (en) 2018-05-02 2019-11-07 The Children's Medical Center Corporation Improved bcl11a micrornas for treating hemoglobinopathies
MX2020012295A (es) 2018-05-15 2021-03-31 Flagship Pioneering Innovations V Inc Composiciones de fusosoma y usos de estas.
DK3806903T5 (da) 2018-06-14 2024-08-19 2Seventy Bio Inc Cd79a kimæriske antigenreceptorer
WO2020014209A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
CN112689516A (zh) 2018-07-11 2021-04-20 细胞基因公司 抗bcma嵌合抗原受体的用途
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
CA3120082A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
WO2020102485A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
US12404500B2 (en) 2018-12-10 2025-09-02 Novo Nordisk A/S Homing endonuclease variants
AU2019395334B2 (en) 2018-12-10 2026-04-23 Regeneron Pharmaceuticals, Inc. PDCD-1 homing endonuclease variants
EP3895052A4 (de) 2018-12-14 2022-10-26 2seventy bio, Inc. Dimerisierungsmittelregulierte immunorezeptorkomplexe
MX2021013588A (es) 2019-05-08 2022-02-11 Medigene Immunotherapies Gmbh Células t genomodificadas.
US12613239B2 (en) 2019-05-10 2026-04-28 Institut Pasteur Live imaging system to visualize the retro-transcribed viral DNA genome
US12109235B2 (en) 2019-06-21 2024-10-08 Kite Pharma, Inc. TGF-beta receptors and methods of use
AU2020341454A1 (en) 2019-09-03 2022-03-10 Sana Biotechnology, Inc. CD24-associated particles and related methods and uses thereof
JP7640538B2 (ja) 2019-10-08 2025-03-05 トラスティーズ オブ ボストン カレッジ 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
CA3160178A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
EP4127144A1 (de) 2020-03-31 2023-02-08 Sana Biotechnology, Inc. Zielgerichtete lipidpartikel und zusammensetzungen und verwendungen davon
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
CN117120085A (zh) 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
EP4501951A3 (de) 2020-08-25 2025-04-30 Kite Pharma, Inc. T-zellen mit verbesserter funktionalität
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
EP3984548A1 (de) 2020-10-16 2022-04-20 Institut Pasteur Generation von lentiviralen vektoren, die es ermöglichen, antigene zum mhc-ii-weg zu leiten und cd4+- und cd8+-t-zellantworten als immunantwort in einem wirt zu induzieren
JP2023550309A (ja) 2020-11-04 2023-12-01 セルジーン コーポレーション 以前に抗がんアルキル化剤療法を受けた患者におけるｃａｒ ｔ細胞療法
EP4272002A1 (de) 2020-12-04 2023-11-08 Celgene Corporation Verwendungen von chimären antigenrezeptor(car)-t-zelltherapien in kombination mit inhibitoren von entzündungsverwandten löslichen faktoren
KR20230124656A (ko) 2020-12-24 2023-08-25 카이트 파마 인코포레이티드 전립선암 키메라 항원 수용체
CA3204161A1 (en) 2021-01-11 2022-07-14 Jagesh Vijaykumar SHAH Use of cd8-targeted viral vectors
US20250319173A1 (en) 2021-03-12 2025-10-16 Institut Pasteur Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
CA3216056A1 (en) 2021-04-16 2022-10-20 Kite Pharma, Inc. Taci/bcma dual binding molecules
AU2022257093A1 (en) 2021-04-16 2023-11-02 Celgene Corporation T cell therapy in patients who have had prior stem cell transplant
US12331315B2 (en) 2021-05-24 2025-06-17 Kite Pharma, Inc. Chimeric antigen receptor
WO2022251712A1 (en) 2021-05-28 2022-12-01 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
CN117730100A (zh) 2021-06-08 2024-03-19 凯德药业股份有限公司 Gpc3结合分子
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
EP4373951A1 (de) 2021-07-19 2024-05-29 2seventy bio, Inc. Vektorherstellungsverfahren
WO2023009989A1 (en) 2021-07-26 2023-02-02 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
US20240344083A1 (en) 2021-08-04 2024-10-17 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
AR127745A1 (es) 2021-10-18 2024-02-28 Kite Pharma Inc Dominios de señalización para receptores quiméricos de antígenos
US20250230511A1 (en) 2021-10-29 2025-07-17 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4472646A1 (de) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Auf cd3 abzielende lentivirale vektoren und verwendungen davon
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharma Multicomponent receptor and signaling complexes
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
IL317172A (en) 2022-05-26 2025-01-01 Regeneron Pharma Lentiviral vector maintenance vehicles and uses thereof
US20260027145A1 (en) 2022-07-27 2026-01-29 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
US20260055146A1 (en) 2022-08-24 2026-02-26 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024064838A1 (en) 2022-09-21 2024-03-28 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
TW202423456A (zh) 2022-10-21 2024-06-16 法商賽拉福柯蒂斯公司 表現選自denv、zikv及yfv之群之黃病毒之非結構抗原、誘導宿主中保護性cd8+t細胞免疫的多核苷酸及慢病毒載體
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025088552A1 (en) 2023-10-25 2025-05-01 Kanglin Biotech (Hangzhou) Co., Ltd. Nucleic acid constructs and uses thereof
WO2025153530A1 (en) 2024-01-16 2025-07-24 Novo Nordisk A/S Albumin-targeted endonucleases, compositions, and methods of use
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025240518A1 (en) 2024-05-14 2025-11-20 Dispatch Biotherapeutics, Inc. Modified lentiviral transfer plasmids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430646T2 (de) * 1993-02-17 2003-01-02 Wisconsin Alumni Research Foundation, Madison Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6004799A (en) * 1996-03-05 1999-12-21 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral DNA vaccines
WO1998039463A2 (en) * 1997-03-06 1998-09-11 Ueberla Klaus Lentivirus based vector and vector system
WO1998046083A1 (en) 1997-04-17 1998-10-22 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7622300B2 (en) 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9825524D0 (en) 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
EP2169073B1 (de) * 1999-10-11 2013-11-13 Institut Pasteur Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
WO2001027304A2 (en) 1999-10-12 2001-04-19 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
EP2292778B1 (de) 2016-09-14
US8460678B2 (en) 2013-06-11
ES2607484T3 (es) 2017-03-31
HK1034283A1 (en) 2001-10-19
FR2777909A1 (fr) 1999-10-29
FR2777909B1 (fr) 2002-08-02
US6682907B1 (en) 2004-01-27
US20100221820A1 (en) 2010-09-02
EP1071804A1 (de) 2001-01-31
CY1112985T1 (el) 2016-04-13
US20120095083A1 (en) 2012-04-19
EP1071804B1 (de) 2012-04-11
US20120252114A1 (en) 2012-10-04
US20120252113A1 (en) 2012-10-04
CA2326719C (fr) 2011-04-12
ES2384553T3 (es) 2012-07-06
WO1999055892A1 (fr) 1999-11-04
PT1071804E (pt) 2012-06-26
JP4571306B2 (ja) 2010-10-27
JP2002512804A (ja) 2002-05-08
EP2292778A1 (de) 2011-03-09
US8367068B2 (en) 2013-02-05
US20060040347A1 (en) 2006-02-23
DK1071804T3 (da) 2012-07-02
AU3427299A (en) 1999-11-16
US7981671B2 (en) 2011-07-19
US8450087B2 (en) 2013-05-28
CA2326719A1 (fr) 1999-11-04

Similar Documents

Publication Publication Date Title
DK1071804T3 (da) Anvendelse af triplex-struktur-dna-sekvenser til overførsel af nukleotidsekvenser
O'Shea-Greenfield et al. Roles of TATA and initiator elements in determining the start site location and direction of RNA polymerase II transcription.
Platt Rho and RNA: models for recognition and response
Charneau et al. HIV-1 reverse transcription A termination step at the center of the genome
Berkhout et al. The leader of the HIV-1 RNA genome forms a compactly folded tertiary structure.
Saccone et al. Structural elements highly preserved during the evolution of the D-loop-containing region in vertebrate mitochondrial DNA
Okamoto et al. Human thioredoxin/adult T cell leukemia-derived factor activates the enhancer binding protein of human immunodeficiency virus type 1 by thiol redox control mechanism
Barat et al. Interaction of HIV-1 reverse transcriptase with a synthetic form of its replication primer, tRNALys, 3
Ohtani et al. Identification of two distinct elements in the long terminal repeat of HTLV‐I responsible for maximum gene expression.
Rounseville et al. Binding of a host cell nuclear protein to the stem region of human immunodeficiency virus type 1 trans-activation-responsive RNA
AU692163B2 (en) Retroviral vector for the transfer and expression of genes for therapeutical purposes in eucaryotic cells
AU2020278864B2 (en) Single base substitution protein, and composition comprising same
DK1792997T3 (da) Lentiviral triplex DNA og vektorer og rekombinante celler indeholdende lentiviralt triplex DNA
EP0331939A3 (de) Verfahren und Zusammensetzungen zum Widerstand gegen Retroviralinfektionen
EP0544894A4 (en) Use of exo-sample nucleotides in gene cloning
Ghosh Glucocorticoid receptor-binding site in the human immunodeficiency virus long terminal repeat
Rezende et al. The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity
Weiss et al. Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA
Martínez-Salas et al. Identification of an essential region for internal initiation of translation in the aphthovirus internal ribosome entry site and implications for viral evolution
Feng et al. Multiple regions of Harvey sarcoma virus RNA can dimerize in vitro
Devare et al. Nucleotide sequence of the transforming gene of simian sarcoma virus.
Csordás-Tóth et al. Structure of the promoter region for the rrnB gene in Eacherichia coli
EP0578776A4 (de) Hemmung von retroviren mittels zu verpackungssequenzen komplementärer antisense-nukleinsäuren.
RU2001131728A (ru) Синтетический ген для экспрессии активного ретровирусного белка в эукариотах
Saggioro et al. Transcriptional block of HTLV-I LTR by sequence-specific methylation